13 March 1998
Protection of Heart and Rejection of Lymphocyte Allografts from the Same Donor in Recipients of Donor-Specific TransfusionsM Jasklowska-Englisz, W L Olszewski, M Maksymowicz, A Ziolkowska
Ann Transplant 1998; 3(1): 28-33 :: ID: 497368
Organ allografts survive in hosts treated with immunosuppressive drugs. The question arises as to whether cells isolated from organ or tissue of an allogeneic donor and transplanted to a genetically disparate recipient can also benefit from the immunosuppressive regimen. We reported previously that the DST (donor specific transfusion) recipients accept heart allografts but reject hyperacutely Lv. infused lymphocytes from the same as DST donor. The present study was devoted to elucidation of the mechanism of these divergent processes. Syngeneic BN hearts and mesenteric lymph node lymphocytes were transplanted to LEW rats pretreated one week previously with donor specific blood transfusions. The allogeneic BN lymphocytes transplanted Lv. to l:EW rats receiving one BN DST were rejected hyperacutely within 6hrs, whereas BN heart grafts transplanted to the BN DST-treated LEW recipients survived 14 :t 2 days. Adoptive transfer of LEW anti-BN DST sera to naive LEW rats caused destruction of the transplanted BN lymphocytes. The LEW BN DST recipients possessed IgG and IgM class alloantibodies binding to BN lymphocytes and heart endothelial cells. mAbs against MHC class I (OX 18) and class II (OX6) antigens neither blocked binding of antibodies of DST-recipient sera to BN lymphocytes nor protected the preincubated BN lymphocytes against destruction after transplantation. Western blot analysis revealed that alloantibodies from DST -recipient sera bound strongly to BN lymphocyte membrane proteins of 60 kd m.w. but not to 45kd and 30kd MHC class I and II proteins. Taken together, DST has no protective effect on intravenously transplanted cells. In contrast, it accelerates the rejection. Alloantibodies present in DST-recipient sera "shield" antigens on the surface of organ allograft endothelial cells. thereby protecting them from recognition and cytotoxic effect. Simultaneously. these alloantibodies "opsonize" the intravenously transplanted lymphocytes and facilitate their halting in lymphoid organs and subsequent lysis. Antibodies other than those directed against MHC seem to mediate both these processes. The results of these studies provide also evidence that the effector mechanism of rejection may be different depending on location of the graft. in the lymphoid as in case of transplanted lymphocytes or in non-lymphoid tissues as heart grafts.
Keywords: Heart Transplant, donor-specific transfusion, Lymphocytes
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588